ONO-7746 Study in Healthy Adult Subject
Launched by ONO PHARMACEUTICAL CO. LTD · Apr 19, 2010
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy non-smoking male or female subjects (18-55 inclusive)
- • Body mass index (BMI) of 19-35 kg/m2 (inclusive)
- • For females, postmenopausal, non-lactating, and non-pregnant
- Exclusion Criteria:
- • History or presence of clinically significant disease
About Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. is a leading Japanese biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs. With a strong focus on oncology, immunology, and central nervous system disorders, Ono leverages cutting-edge technology and scientific expertise to advance its pipeline of novel treatments. Committed to enhancing patient outcomes, Ono collaborates with global partners and invests in clinical trials to bring transformative medicines to market, exemplifying its mission to improve health and quality of life worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Austin, Texas, United States
Patients applied
Trial Officials
Ono Pharma USA, Inc.
Study Director
Ono Pharmaceutical Co. Ltd
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials